A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Aug 2017
At a glance
- Drugs Mongersen (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors Celgene Corporation
- 21 Jul 2017 Planned End Date changed from 24 Feb 2018 to 18 Oct 2018.
- 21 Jul 2017 Planned primary completion date changed from 2 Dec 2017 to 17 Sep 2018.
- 21 Jul 2017 Planned initiation date changed from 15 Apr 2017 to 2 Oct 2017.